Ys Biopharma Co Stock Fundamentals

YS Stock   1.02  0.11  12.09%   
YS Biopharma Co fundamentals help investors to digest information that contributes to YS Biopharma's financial success or failures. It also enables traders to predict the movement of YS Biopharma Stock. The fundamental analysis module provides a way to measure YS Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to YS Biopharma stock.
Selling General Administrative is likely to gain to about 87.4 M in 2024, whereas Tax Provision is likely to drop slightly above 969.1 K in 2024.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

YS Biopharma Co Company Shares Outstanding Analysis

YS Biopharma's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Shares Outstanding

 = 

Public Shares

-

Repurchased

More About Shares Outstanding | All Equity Analysis

Current YS Biopharma Shares Outstanding

    
  188.33 M  
Most of YS Biopharma's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, YS Biopharma Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

YS Biopharma Shares Outstanding Historical Pattern

Today, most investors in YS Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various YS Biopharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of YS Biopharma shares outstanding as a starting point in their analysis.
   YS Biopharma Shares Outstanding   
       Timeline  
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition

YS Biopharma Common Stock Shares Outstanding

Common Stock Shares Outstanding

101.72 Million

At this time, YS Biopharma's Common Stock Shares Outstanding is comparatively stable compared to the past year.
Based on the latest financial disclosure, YS Biopharma Co has 188.33 M of shares currently outstending. This is 4.32% higher than that of the Biotechnology sector and 76.25% higher than that of the Health Care industry. The shares outstanding for all United States stocks is 67.07% higher than that of the company.

YS Biopharma Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining YS Biopharma's current stock value. Our valuation model uses many indicators to compare YS Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across YS Biopharma competition to find correlations between indicators driving YS Biopharma's intrinsic value. More Info.
YS Biopharma Co is rated below average in return on equity category among related companies. It is rated first in return on asset category among related companies . At this time, YS Biopharma's Return On Equity is comparatively stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value YS Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for YS Biopharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the YS Biopharma's earnings, one of the primary drivers of an investment's value.

YS Biopharma Shares Outstanding Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses YS Biopharma's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of YS Biopharma could also be used in its relative valuation, which is a method of valuing YS Biopharma by comparing valuation metrics of similar companies.
YS Biopharma is currently under evaluation in shares outstanding category among related companies.

YS Biopharma Fundamentals

About YS Biopharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze YS Biopharma Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of YS Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of YS Biopharma Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.6 M2.5 M
Total Revenue790.3 M530.6 M
Cost Of Revenue176.4 M121 M
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.14  0.13 
Research And Ddevelopement To Revenue 0.42  0.34 
Capex To Revenue(0.07)(0.08)
Revenue Per Share 6.65  4.17 
Ebit Per Revenue(0.18)(0.19)

Pair Trading with YS Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if YS Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in YS Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving against YS Biopharma Stock

  0.78VRDN Viridian TherapeuticsPairCorr
  0.78LRMR Larimar TherapeuticsPairCorr
  0.74KROS Keros TherapeuticsInc Earnings Call This WeekPairCorr
  0.69JNJ Johnson Johnson Financial Report 18th of July 2024 PairCorr
  0.67MRSN Mersana TherapeuticsPairCorr
The ability to find closely correlated positions to YS Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace YS Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back YS Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling YS Biopharma Co to buy it.
The correlation of YS Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as YS Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if YS Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for YS Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether YS Biopharma is a strong investment it is important to analyze YS Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact YS Biopharma's future performance. For an informed investment choice regarding YS Biopharma Stock, refer to the following important reports:
Check out YS Biopharma Piotroski F Score and YS Biopharma Altman Z Score analysis.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for YS Biopharma Stock analysis

When running YS Biopharma's price analysis, check to measure YS Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy YS Biopharma is operating at the current time. Most of YS Biopharma's value examination focuses on studying past and present price action to predict the probability of YS Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move YS Biopharma's price. Additionally, you may evaluate how the addition of YS Biopharma to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bonds Directory
Find actively traded corporate debentures issued by US companies
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Money Managers
Screen money managers from public funds and ETFs managed around the world
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Is YS Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of YS Biopharma. If investors know YS Biopharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about YS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
9.461
Earnings Share
(0.57)
Revenue Per Share
4.67
Quarterly Revenue Growth
(0.09)
Return On Assets
(0.10)
The market value of YS Biopharma is measured differently than its book value, which is the value of YS Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of YS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is YS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because YS Biopharma's market value can be influenced by many factors that don't directly affect YS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between YS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if YS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, YS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.